Algert Global LLC Sells 7,330 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Algert Global LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,042 shares of the company’s stock after selling 7,330 shares during the quarter. Algert Global LLC owned approximately 0.06% of Intellia Therapeutics worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP grew its position in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock worth $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in Intellia Therapeutics in the 2nd quarter worth approximately $679,000. American Century Companies Inc. lifted its holdings in Intellia Therapeutics by 23.8% in the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock worth $7,397,000 after buying an additional 63,550 shares during the period. Comerica Bank lifted its holdings in Intellia Therapeutics by 853.6% in the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after buying an additional 33,214 shares during the period. Finally, ARK Investment Management LLC lifted its holdings in Intellia Therapeutics by 5.7% in the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after buying an additional 659,651 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NTLA shares. The Goldman Sachs Group dropped their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Chardan Capital increased their price objective on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, November 18th. William Blair restated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Finally, Robert W. Baird lowered their target price on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.20% of the company’s stock.

Intellia Therapeutics Trading Up 3.3 %

Intellia Therapeutics stock opened at $15.21 on Friday. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -2.80 and a beta of 1.81. The stock has a fifty day simple moving average of $17.38 and a two-hundred day simple moving average of $21.47. Intellia Therapeutics, Inc. has a 12 month low of $12.82 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.38) EPS. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.13 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.